Arbogast Pharmaceuticals is focused to development of \ a diagnostic test and drugs around the discovery of one toxic and one protective component in blood. Very-low density lipoproteins (VLDL) were found to be toxic to cells in culture. They are similar to low density lipoproteins (LDL) which transport cholesterol. The protective factor, named Toxicity Preventing Activity (TxPA), was found to counteract the toxicity of VLDL to cells in culture. The ratio of the toxic component (VLDL) to the protective component (TxPA) determines whether cells live or die in tissue culture. The ratio of these two components in blood has been extremely predictive of preeclampsia in clinical studies of pregnant women. The company has recently developed the assay of TxPA to a state where it is commercially viable and has filed domestic and international patents on the improved assay. This inexpensive blood chemistry test for TxPA would have wide clinical applicability in areas such as atherosclerosis, hospital admission and aging. The initial focus of the company will be to bring the TxPA test to market for preeclampsia. However, because the TxPA technology represents a completely new theory in medicine, there may be multiple drug opportunities.
